Liquidia Corporation (LQDA)
Nasdaq: LQDA · Pharmaceutical Preparations · Morrisville, NC · filing with the SEC since 2020
Who owns Liquidia Corporation
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 11.9% of Common Stock, as its SCHEDULE 13G/A filed Jul 8, 2026 says.
Directors and officers
18
report now, of 22 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · Common Stock
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 9, 2026 · Common Stock, par value $0.001 per share (the "Shares") · 9.95% in Nov 12, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 4, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Paul B Manning
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share
Legend Aggregator, LP
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What LQDA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Liquidia PAH
An entity · legal entity · owns, named in the 10-K filed Mar 5, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
175sales
1purchases
104sales on a scheduled plan
15people selling
$231Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Oct 28, 2025 to Oct 28, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 28, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window15 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Bloch Stephen M | director | 49 | $125M | 0 | 0 | $0 |
| Jeffs Roger | Chief Executive Officer | 27 | $32.2M | 27 | 0 | $0 |
| Kaseta Michael | CFO and COO | 13 | $16.2M | 13 | 0 | $0 |
| Manning Paul B | director | 5 | $12.8M | 0 | 0 | $0 |
| Saggar Rajeev | Chief Medical Officer | 10 | $11.3M | 5 | 0 | $0 |
| Adair Jason | Chief Business Officer | 14 | $7.9M | 14 | 0 | $0 |
| Moomaw Scott | Chief Commercial Officer | 11 | $5.7M | 11 | 0 | $0 |
| Rielly-Gauvin Katherine | director | 2 | $4.1M | 2 | 0 | $0 |
| Krepp Sarah | Chief Human Resource Officer | 12 | $3.8M | 10 | 0 | $0 |
| Singh Raman | director | 4 | $3.7M | 0 | 0 | $0 |
| Schundler Russell | General Counsel | 7 | $3.1M | 7 | 0 | $0 |
| Boyle Dana | Chief Accounting Officer | 13 | $2.5M | 11 | 0 | $0 |
| Kirsch Arthur S | director | 3 | $1.7M | 0 | 0 | $0 |
| Khindri Sanjeev | Chief Development Officer | 4 | $400,000 | 4 | 0 | $0 |
| Johnson David Edward | director | 1 | $300,000 | 0 | 1 | $300,000 |